Diagnostic Performance of [68Ga]Ga-HKG301 (FAP-2286) PET/CT in Biologic Borderline Resectable Pancreatic and Invasive Lobular Breast Cancers – FAPTRACE Trial
Sponsor: Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Phase: 2
Disease: Pancreatic ductal adenocarcinoma, Invasive lobular breast carcinoma
EU trial number: 2026-526498-40-00
Population: Adults (≥18 years) newly diagnosed with primarily resectable suspected or histologically confirmed pancreatic ductal adenocarcinoma and serum CA19-9 >500 U/mL and/or inconclusive conventional metastatic staging; or women aged ≥18 years with histologically confirmed, previously untreated invasive lobular breast cancer with HER2-positive or ER <10% status at any stage, or clinical stage II (≥cT2) or III. Participants require ECOG ≤2, suitable renal function (creatinine clearance ≥60 mL/min) and ability to undergo PET/CT.
Register Investigator Interest
Interested in offering this trial to suitable patients?